Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population by White, Marquitta J et al.
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Published works by 
Dartmouth faculty Faculty Work 
8-31-2015 
Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a 
Ghanaian Population 
Marquitta J. White 
Dartmouth College 
Nuri M. Kodaman 
Dartmouth College 
Reed H. Harder 
Dartmouth College 
Folkert W. Asselbergs 
University Medical Center Utrecht 
Douglas E. Vaughan 
Northwestern University 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Dartmouth Digital Commons Citation 
White, Marquitta J.; Kodaman, Nuri M.; Harder, Reed H.; Asselbergs, Folkert W.; Vaughan, Douglas E.; 
Brown, Nancy J.; Moore, Jason H.; and Williams, Scott M., "Genetics of Plasminogen Activator Inhibitor-1 
(PAI-1) in a Ghanaian Population" (2015). Open Dartmouth: Published works by Dartmouth faculty. 2737. 
https://digitalcommons.dartmouth.edu/facoa/2737 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Published works by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 
Authors 
Marquitta J. White, Nuri M. Kodaman, Reed H. Harder, Folkert W. Asselbergs, Douglas E. Vaughan, Nancy 
J. Brown, Jason H. Moore, and Scott M. Williams 
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/2737 
RESEARCH ARTICLE
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Abstract
Plasminogen activator inhibitor 1 (PAI-1), a major modulator of the fibrinolytic system, is an
important factor in cardiovascular disease (CVD) susceptibility and severity. PAI-1 is highly
heritable, but the few genes associated with it explain only a small portion of its variation.
Studies of PAI-1 typically employ linear regression to estimate the effects of genetic variants
on PAI-1 levels, but PAI-1 is not normally distributed, even after transformation. Therefore,
alternative statistical methods may provide greater power to identify important genetic vari-
ants. Additionally, most genetic studies of PAI-1 have been performed on populations of
European descent, limiting the generalizability of their results. We analyzed >30,000 vari-
ants for association with PAI-1 in a Ghanaian population, using median regression, a non-
parametric alternative to linear regression. Three variants associated with median PAI-1,
the most significant of which was in the gene arylsulfatase B (ARSB) (p = 1.09 x 10−7). We
also analyzed the upper quartile of PAI-1, the most clinically relevant part of the distribution,
and found 19 SNPs significantly associated in this quartile. Of note an association was
found in period circadian clock 3 (PER3). Our results reveal novel associations with median
and elevated PAI-1 in an understudied population. The lack of overlap between the two
analyses indicates that the genetic effects on PAI-1 are not uniform across its distribution.
They also provide evidence of the generalizability of the circadian pathway’s effect on PAI-
1, as a recent meta-analysis performed in Caucasian populations identified another circa-
dian clock gene (ARNTL).
Introduction
Cardiovascular disease (CVD) consists of multiple conditions with overlapping environ-
mental and genetic risk factors, symptoms, and disease etiologies. It causes ~48% of all
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non-communicable disease-related deaths worldwide[1]. Thrombosis is a major factor in
CVD, including myocardial infarction (MI) and stroke, representing an excellent target for
CVD prevention and treatment[2]. Fibrinolysis, the process by which the clotting protein
fibrin is cleaved by plasmin, moderates thrombotic events[3]. Impairment of the fibrinolytic
balance is due in part to increased plasminogen activator inhibitor-1 (PAI-1) and associates
with thrombotic risk and severity [4]. Although several studies of plasma PAI-1 levels indi-
cate a positive correlation with susceptibility to thromboembolism, atherosclerosis, and MI,
the nature of the relationship between PAI-1 and CVD risk remains inadequately defined
[5,6].
PAI-1 levels are influenced by genetic variation, with heritability estimates ranging between
0.42–0.71[7–9]. The most studied genetic variant, impacting PAI-1 levels, is the 4G/5G pro-
moter polymorphism. This variant influences circulating PAI-1 levels in a dose-dependent
manner, with carriers of the 4G allele exhibiting higher levels of circulating PAI-1[10]. How-
ever, this variant alone does not account for most of the PAI-1’s heritability. Other variants
must also play a significant role in the variation of PAI-1 levels[10]. The majority of studies
aimed at uncovering these variants have been conducted in Caucasian populations [11]. Few
studies have been performed on African populations, most notably using a population-based
cohort form the Brong Ahafo region in Sunyani, Ghana[12,13]. These African-based studies,
however, were candidate gene analyses focusing on a relatively small number of nucleotide
polymorphisms (SNPs). A small number of other studies have investigated racial/ethnic group
differences in mean PAI-1 levels [14–17]. While the results from these reports are highly vari-
able, the non-normal nature of the PAI-1 distribution is a highly conserved feature, regardless
of racial/ethnic group.
A possibly limiting factor in elucidating the genetic bases of PAI-1 has been the use of lin-
ear regression to determine the association of SNPs with PAI-1 levels. This may not be an
appropriate analytical method as PAI-1 is highly skewed[18]. Furthermore, using the mean to
assess the effect of SNPs on PAI-1 in the presence of extreme values can also lead to incorrect
inference[19]. Therefore, the median of the distribution may be a more appropriate measure
of the overall behavior of PAI-1 levels in response to genotype. Quantile regression is a non-
parametric alternative to linear regression that parallels standard linear regression conceptu-
ally, but makes no assumptions about the distribution of residual errors, and is therefore
robust to skewness and heteroskedasticity in the phenotypic distribution [18,20,21]. Quantile
regression can be used to assess the impact of any percentile of the phenotypic distribution.
We applied quantile regression to assess the effect of genotype on the median of the PAI-1
distribution.
Both median regression and standard linear regression assume uniform effects of the inde-
pendent variable on the dependent variable, for which there is no theoretical justification or
empirical support in the case of PAI-1. Recent evidence from genetic studies of other biological
traits raises the possibility that genetic variants exhibit quantile-specific effects [19,22], but this
has been ignored in most genetic studies and all previous studies of PAI-1. Quantile regression
can be used to estimate the effects of specific genetic variants in different parts of the pheno-
typic distribution[19]. This may be of special interest when specific ranges of a distribution
relate to a particular clinical endpoint. Since elevated PAI-1 levels are associated with CVD, the
impact of genetic variants in different quantiles of the PAI-1 distribution may be of special clin-
ical interest. Quantile regression has been used sparingly in human genetics studies although it
has been used more extensively other fields[19]. We explicitly tested the hypothesis that there
are genetic factors with non-uniform and/or non-linear effects on plasma PAI-1 by performing
quantile regression on the 75th percentile of PAI-1 values.
Genetics of PAI-1 in Ghana
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Methods
Study Cohort Description
All participants provided written consent for this study. The study comprised a subset of 1105
unrelated individuals recruited from Sunyani, Ghana recruited between 2002 and 2005 [23].
We examined a subset of the cohort previously assessed [12,13] (n = 992) and an additional
113 subjects from the 90th percentile of the plasma PAI-1 distribution. Ascertainment, DNA
collection and biomarker measurement protocols are described elsewhere[23]. DNA and
demographic data including age, body mass index (BMI), triglycerides and PAI-1 levels, were
collected for all study participants. This study was approved by the Committee for the Protec-
tion of Human Subjects at Dartmouth College.
Genotyping Scheme
DNA was genotyped using the Illumina Infinium HumanExome BeadChip (Exome Chip) plat-
form (Illumina, Inc., San Diego, CA). The Exome Chip provides coverage of the exonic regions
of the genome, using approximately 240,000 markers. We supplemented these with an addi-
tional 8,439 common variants selected to target genes with prior evidence of association with
variation in CVD.
Quality Control Procedures
Participants with genotyping efficiency less than 95% were excluded from further analysis. Sub-
jects who were missing demographic and/or biomarker data were also excluded from the
study. After quality control (QC) procedures, 1053 individuals (441 males, 612 females)
remained. A total of 39,124 common variants (minor allele frequency 0.05) were analyzed
from the Exome Chip genotype data. QC criteria for the selection of common variants included
a genotyping efficiency> 95% and a Hardy-Weinberg equilibrium p-value> 0.001, after
which 38,871 variants remained. All QC was carried out with PLINK[24].
Preliminary Analyses
The distributions of demographic and biological variables were assessed in males and females,
separately, to determine if any significant differences existed between sexes. Normality of con-
tinuous traits was evaluated using the Shapiro-Wilk test (p< 0.05). For normally distributed
continuous variables, the Student’s t test was used to assess mean differences between sexes. In
cases of non-normality, the Wilcoxon rank sum test was used. For discrete variables, the Chi-
square test was used. Analyses were performed using STATA 11[25].
To be included in the study, both parents and both sets of grandparents had to be native to
Ghana, reducing likelihood of population stratification. However, as an added precaution, we
explicitly tested for substructure using STRUCTURE[26]. This analysis was performed using
8521 variants pruned for LD (r2 = 0.5) and present in the JPT+CHB, YRI, and CEU HapMap
data. STRUCTURE runs used an admixture model with correlated allele frequencies (burn-
ins = 10,000; iterations = 10,000) in a supervised analysis with K = 3. STRUCTURE analysis
revealed no significant evidence of population stratification within our dataset (S1 Fig).
Median Regression Analysis
The distribution of PAI-1 levels was tested for normality and found to deviate even after log
transformation (Shapiro-Wilk test p< 0.001). Therefore, median regression was performed
with the quantreg package in R[27]. Regression models were adjusted for age, sex, BMI, triglyc-
erides, and genotype at the PAI-1 4G/5G variant. Triglyceride levels were log-transformed.
Genetics of PAI-1 in Ghana
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Single variant results were visualized using the qqplots package in R [28]. Because a large num-
ber of the variants genotyped were in moderate to high LD, Bonferroni correction was deemed
overly conservative. Therefore, False Discovery Rate (FDR) was also used to correct for multi-
ple testing. FDR is more robust to the violation of the independent test assumption, providing
moderate control of type I error. Results were considered statistically significant if p< 2.57x10-
6 (FDR q = 0.1).
To test if median regression exhibited greater sensitivity to detect linear and non-linear
effects than linear regression, we constructed linear regression models for SNPs found to be sig-
nificant with median regression. Linear regression models were adjusted for the covariates
above. Analyses were performed with STATA 11[25].
Additive models were used, with the major allele as referent. In cases where there were
fewer than five individuals in a genotype group, SNPs were coded dominantly for the effect of
the minor allele, i.e., the homozygous minor and heterozygote genotype groups were combined
into one class and compared to the homozygous major genotype.
Exploratory Upper PAI-1 Quartile Regression
Because the upper extremes of the PAI-1 distribution associate with clinical outcomes, we per-
formed upper quartile regression to assess the impact of single variants within this target region
of the PAI-1 distribution [29,30]. The quantreg package in R was used [28], with the option for
robust standard errors. SNPs were coded as described above. For gene regions contained more
than one associating variant, pairwise LD was assessed using Haploview [31].
Bioinformatic / Data Mining Investigation of Associating markers
We used the Function SNP Prediction (FuncPred) pipeline in SNPnfo [32] that incorporates
several software tools/web servers such as PolyPhen [33], SNPs3D[34], MATCH[35], and ESE-
finder [36] to assess the possibility that SNPs affect biological function (i.e. protein structure/
stability, exon splicing, transcription, etc.).
Results
Cohort Demographics
There were no significant differences in mean age, triglyceride levels, plasma PAI-1 levels, or
distribution of PAI-1 4G/5G variant genotypes between sexes (Table 1). Females had higher
BMIs than males (p< 0.001).
Median Regression Analyses
Three non-synonymous single nucleotide polymorphisms (SNPs) significantly associated with
circulating PAI-1 levels after Bonferroni correction. These were SNPs rs1071598 (p = 1.09 x
10−7), rs61997065 (p = 3.56 x 10−7), and rs10406453 (p = 2.58 x 10−7), located on chromosomes
5, 7, and 19, respectively (Table 2, Fig 1). Of these variants, rs1071598, a missense SNP located
in the arylsulfatase B (ARSB) gene, and rs10406543, a missense variant in leukocyte receptor
cluster member 9 (LENG9) had similar effects on median PAI-1 levels (rs1071598 β = -0.442,
rs10406543 β = -0.467; where β represents the allelic effect on the natural log transformed PAI-
1 level.) (Table 2). In contrast, rs61997065, in carboxypeptidase A2 (CPA2), displayed a strong
positive effect on median PAI-1 levels (β = 0.503) (Table 2).
We tested the five significant or marginally significant SNPs (p< 10−5) using standard lin-
ear regression models adjusted for the same covariates as above (S1 Table). For each SNP, the
effect trended in the same direction; however, in every model, the standard error reported by
Genetics of PAI-1 in Ghana
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linear regression was greater than that reported by median regression. This resulted in larger
95% confidence intervals and larger p-values, confirming that median regression in a skewed
data set can increase sensitivity (S1 Table).
We also evaluated the effect of the PAI1 4G/5G promoter polymorphism (rs1799768),
shown in multiple populations to have a strong impact on PAI-1 levels [11,13], using both
median regression and standard linear regression (Table 2, S1 Table). Association results from
the two regression methods were comparable (linear regression β = 0.25; p = 1.30 x 10−4 and
median regression β = 0.27; p = 1.84 x 10−4).
Quartile Regression Analyses
Quantile regression analyses were performed on the upper quartile of the PAI-1 distribution.
Nineteen variants were significant after correction for multiple testing with FDR (Table 3, Fig
2). The most significant effect in the upper quartile of the PAI-1 distribution was observed for
rs4755779, located on chromosome 11 (p = 1.44 x 10−10), while the largest negative and positive
effects were observed for rs10462021 (β = -0.434), located on chromosome 1, and rs116307792
(β = 0.249), located on chromosome 3 (Table 3). Of note, a 72.6kb region on chromosome 11
containing both the pleckstrin homology-like domain, family B,member 1 (PHLDB1) and
Table 1. HeART cohort gender-separated demographics.
Males (n = 441) Females (n = 612) P-Valuea.
Age (years) 44.02(12.47) 43.22(10.75) 0.523
Body Mass Index 24.21(4.29) 27.08(5.44) <0.001
Triglycerides 94.45(52.85) 93.89(56.24) 0.489
serum PAI-1 levels 7.96(8.90) 8.84(11.02) 0.930
PAI-1 4G/5G 4G/4G 20 34 0.264b
4G/5G 108 171
5G/5G 260 332
a. P-values are from the Wilcoxon Rank Sum test unless otherwise indicated.
b. P-values are derived from the Chi-square test of association.
doi:10.1371/journal.pone.0136379.t001
Table 2. Median Regression Results for Single Variant association with circulating Plasminogen Activator Inhibitor 1 (PAI1) levels. Results that
remained significant after FDR correction are highlighted in bold; only a subset of significant results are presented above (p-value 10−5).




4 SLC7A11 rs4479754 -0.293 0.064 -0.418 -0.168 4.67E-06
5 ARSB rs1071598 -0.442 0.083 -0.604 -0.280 1.09E-07‡
7 CPA2 rs61997065 0.503 0.098 0.311 0.695 3.56E-07‡
19 LENG9 rs10406453 -0.467 0.090 -0.643 -0.290 2.58E-07‡
19 LENG8 rs1035451 -0.375 0.080 -0.532 -0.219 2.90E-06
7 SERPINE1 rs1799768 (PAI-1 4G/5G) 0.266 0.071 0.123 0.405 1.84E-04
a.Beta coefficient from median regression model represents the effect of the minor allele; model covariates: age, sex, BMI, triglycerides, and PAI1 4G/5G
variant genotype.
b.SE; Standard error; robust standard errors are reported above. LL = 95% Confidence Interval lower limit; UL = 95% Confidence Interval upper limit
‡Effect remained significant after Bonferroni correction (threshold = 1.29E-06)
doi:10.1371/journal.pone.0136379.t002
Genetics of PAI-1 in Ghana
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trehalase (TREH) genes (PHLDB1/TREH gene region) harbored three SNPS that were signifi-
cantly associated in the upper quartile, two of which (rs7389 and rs519982) remained significant
after Bonferroni correction.
Discussion
Susceptibility to major thrombotic events is increased by unbalanced or impaired fibrinolysis,
which is heavily impacted by variation in PAI-1 levels. Our results identified three novel vari-
ants that significantly associated with median PAI-1. We further postulated that the effects of
genetic variants on PAI-1 were non-uniform across its distribution, and tested this hypothesis
by investigating the impact of common variants on the clinically relevant upper quartile. We
found 19 SNPs that were significantly associated with PAI-1 levels in the upper quartile,
Fig 1. Manhattan Plot of Common Variant Association Analysis with Median plasma PAI-1.Only markers on chromosomes 1–22 are presented above;
regions from the X chromosome, Y chromosome, pseudo-autosomal region of the X chromosome, and mitochondrial markers have been excluded.
Statistically significant markers are labeled in bold. Red Line represents FDR significance threshold (2.57 x 10−6).
doi:10.1371/journal.pone.0136379.g001
Genetics of PAI-1 in Ghana
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including one region that harbored multiple associating variants. Our study not only revealed
novel associations with PAI-1 levels but also found the first evidence for association in an Afri-
can population of quartile-specific effects on PAI-1 levels.
Median regression
Of the three SNPs that associated with median PAI-1, rs1071598 was the most significant.
Located within the fourth exon of ARSB, rs1071518 is responsible for a valine to methionine
amino acid change at position 376 (V376M) that is classified as “probably benign” with respect
to its effect on ARSB protein function[32]. Although there is no strong evidence that this
SNP affects ARSB protein function, the V376M substitution may affect structural stability.
Table 3. Upper Quartile Regression Results for Single Variant association with circulating Plasminogen Activator Inhibitor 1 (PAI-1) levels. Results
that remained significant after FDR correction are highlighted in bold; only a subset of significant results are presented above (p-value 10−6).




1 COL16A1 rs72887331 -0.277 0.053 -0.381 -0.172 2.64E-07‡
1 FHAD1 rs12126178 -0.133 0.026 -0.184 -0.083 2.64E-07‡
1 PER3 rs10462021 -0.434 0.091 -0.613 -0.256 2.07E-06
2 PLEKHB2 rs6713972 -0.234 0.037 -0.308 -0.161 5.14E-10‡
3 — rs13314993 0.212 0.041 0.132 0.293 2.85E-07‡
3 — rs33483 0.202 0.045 0.113 0.291 9.48E-06
3 SLC15A2 rs116307792 0.249 0.047 0.158 0.340 1.08E-07‡
5 ADAMTS12 rs61757473 -0.375 0.063 -0.500 -0.252 3.26E-09‡
5 RAPGEF6 rs61757473 -0.178 0.039 -0.254 -0.103 4.43E-06
6 TAGAP rs35263580 -0.198 0.033 -0.263 -0.133 4.14E-09‡
7 — rs2023783 -0.432 0.079 -0.586 -0.278 4.97E-08‡
9 DBH rs4531 -0.195 0.038 -0.270 -0.120 4.19E-07‡
9 NMRK1 rs35472028 -0.274 0.059 -0.391 -0.158 4.19E-06
11 EXT2 rs4755779 -0.213 0.033 -0.277 -0.148 1.44E-10‡
PHLDB1 / TREH rs7389 -0.252 0.049 -0.349 -0.155 3.70E-07‡
11 PHLDB1 / TREH rs2077173 -0.256 0.055 -0.363 -0.149 3.05E-06
TREH rs519982 -0.259 0.051 -0.360 -0.158 5.75E-07‡
12 OR1OP1 rs76940436 -0.268 0.046 -0.359 -0.177 1.00E-08‡
12 P2RX7 rs34219304 -0.302 0.062 -0.423 -0.181 1.09E-06‡
14 FAM161B rs34834232 -0.258 0.053 -0.361 -0.155 1.13E-06‡
14 NID2 rs2273430 -0.239 0.050 -0.338 -0.141 2.32E-06
16 C1QTNF8 rs73494080 -0.283 0.057 -0.395 -0.170 9.82E-07‡
17 — rs4796217 -0.211 0.046 -0.301 -0.121 4.94E-06
17 CEP95 rs9910506 -0.327 0.066 -0.457 -0.198 8.70E-07‡
17 SECTM1 rs113432525 -0.276 0.060 -0.394 -0.157 5.63E-06
19 ERVV-1 rs10403404 -0.201 0.045 -0.289 -0.114 7.60E-06
19 PDE4C rs1444689 0.224 0.050 0.125 0.322 9.16E-06
22 C22orf43 rs75824255 0.185 0.040 0.106 0.263 4.92E-06
a.Beta coefficient from median regression model represents the effect of the minor allele; model covariates: age, sex, BMI, triglycerides, and PAI1 4G/5G
variant genotype.
b.SE; Standard error; robust standard errors are reported above. LL = 95% Confidence Interval lower limit; UL = 95% Confidence Interval upper limit
‡Effect remained significant after Bonferroni correction (threshold = 1.29E-06)
doi:10.1371/journal.pone.0136379.t003
Genetics of PAI-1 in Ghana
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Methionine to valine substitutions are predicted to cause over-packing of protein cores, as
methionine is a larger amino acid than valine, possibly influencing protein stability[37].
According to SNPinfo, rs1071598 is located within two base pairs of a putative exon splice
enhancer motif, potentially affecting the relative frequency of splice variants. ARSB has been
implicated in reactive oxidative species (ROS) production and the activation of ROS-mediated
inflammatory cascades [38]. ARSB also has the ability both to replicate and mediate the effects
of hypoxia in human tissue [39]. PAI-1 was recently identified as a hypoxia inducible gene, and
has long been established as a biomarker of inflammation [40]. The shared connection with
inflammatory responses of ARSB and PAI-1 presents a potential link between PAI-1 levels and
genetic variants in ARSB.
Fig 2. Manhattan Plot of Common Variant Association Analysis with Upper Quartile of PAI-1 distribution.Only markers on chromosomes 1–22 are
presented above; regions from the X chromosome, Y chromosome, pseudo-autosomal region of the X chromosome, and mitochondrial markers have been
excluded. Top three significant markers are labeled in bold. Red Line represents FDR significance threshold (2.57 x 10−6). Loci with more than one significant
variant are signified by a box. Noteworthy significant associations are labeled in bold.
doi:10.1371/journal.pone.0136379.g002
Genetics of PAI-1 in Ghana
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Another SNP, rs61997065, located in the only exon of LENG9, has an effect similar to the
ARSB SNP. It causes a histidine to arginine substitution (H153R) predicted to be benign with
respect to protein function. LENG9 is a member of the leukocyte receptor complex (LRC), an
extended gene region on chromosome 19 that encodes immunoglobulin superfamily receptors
[41]. Although LENG9 has been mapped to the LRC, its function is unknown.
The only SNP that associated with increased PAI-1 levels was rs61997065, located in CPA2,
which causes a valine to isoleucine substitution (V67I). This SNP is proximal to a predicted
exon splice enhancer motif, indicating a possible biological role[32]. CPA2 is a digestive exo-
peptidase found primarily in the pancreas that is also expressed in the brain, in both humans
and rats [42,43]. Previous studies revealed a possible regulatory role of extrapancreatic CPA2
in the renin-angiotensin system (RAS) via differential processing of Angiotensin I [44,45].
There are multiple sources linking the RAS and the fibrinolytic system [46,47]. Additionally,
genetic variants of the RAS have been previously associated with mean PAI-1 levels in both
Caucasian and African populations [12,48].
Upper quartile regression
Upper quartile regression analyses identified 19 associating variants; of particular note
among these variants were 1) two non-synonymous SNPs located in genes with a plausible
connection to PAI-1, rs4755779 in EXT2 and rs10462021 in PER3, and 2) three SNPs located
in the PHLBD1/TREH gene region on chromosome 11.
The EXT2 SNP, rs4755779, is a missense variant that causes a methionine to valine substitu-
tion (M42V), predicted to be benign with respect to protein function. EXT2 encodes a protein
involved in heparin sulfate biosynthesis, and associates with hereditary multiple exostoses and
type 2 diabetes [49,50]. A plausible biological connection exists between EXT2 and PAI-1 via
heparin-binding growth factors (HBGF). HBGFs have been implicated in the modulation of
PAI-1 expression. In particular, HBGF-1 inhibits PAI-1 expression in human umbilical vein
endothelial cells [51].
An associating missense variant in PER3, rs10462021, is responsible for a histidine to argi-
nine substitution (H1139R), and is predicted to have an effect on protein function, although
the nature of this effect is unclear. PER3 is a member of the circadian rhythm pathway that
affects inflammatory responses by increasing the secretion of pro-inflammatory cytokines [52].
Previous studies in model organisms have also reported an association between PER3 and sus-
ceptibility to CVD, and transgenic PER3 knockout mice showed increased susceptibility to
arteriosclerotic disease[53]. The identification of rs10462021 in PER3 is particularly notewor-
thy because variants in another prominent member of the circadian rhythm pathway, aryl
hydrocarbon receptor nuclear translocator-like gene (ARNTL), were found to be associated with
PAI-1 levels in a recent meta-analysis performed on Caucasians [11]. PER3 and ARNTL are
major regulators of the circadian clock mechanism, a transcriptional timing apparatus gov-
erned by multiple positive and negative feedback loops[54]. ARNTL forms a heterodimer with
CLOCK, which drives transcription of the PER and CRY gene families. PER and CRY then het-
erodimerize to form a complex that acts as an inhibitor of the ARNTL/CLOCK complex, creat-
ing a negative feedback loop[54] (Fig 3). The interaction between the PER3/CRY and ARTNL/
CLOCK heterodimers is of note because there is substantial evidence that ARNTL/CLOCK
activates the PAI-1 promoter and increases PAI-1 expression [55,56].
The effects of PER3 and ARNTL on PAI-1 variation may be population specific, but the
involvement of the circadian rhythm pathway appears to be generalizable. A difference in allele
and genotype frequencies at the PER3 variant, rs10462021, may be responsible, in part, for a
population-specific effect as found in a study comparing world-wide populations[58]. Allele
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frequency differences between African and European descent populations may affect the ability
to detect or replicate the effects of this variant. However, the fact that multiple circadian clock
genes have been associated with PAI-1 indicates the importance of the pathway despite possi-
bly variable effects of specific genes.
We also discovered a 72.6kb region on chromosome 11, containing two genes, PHLBDI and
TREH, with multiple associating variants. Of the three variants identified in this region, two
(rs519982 and rs7389) passed correction for multiple testing. All three SNPs were in high LD
with each other (0.94< r2 < 0.97), indicating that they represent a single association signal,
making functional predictions difficult. However, we can speculate based on the putative indi-
vidual SNP functions. Rs519982 is located in a region predicted to contain a transcription
factor binding motif 14.9kb upstream of the TREH start codon. Its predicted location in a tran-
scription factor binding site proximal to the TREH gene boundary may have functional impli-
cations; rs7389 is located in the 3’ UTR of PHLDB1 and is predicted to affect microRNA
(miRNA) binding site activity that can inhibit protein translation[59].
Our second most significant association, rs6713972, located in pleckstrin homology domain
containing family B member 2 (PLEKHB2), is in the same family as PHLDB1. Deficiency in
another member of the pleckstrin homology containing gene family, pleckstrin homology-like
domain, family A,member 1 (PHLDA1) has been shown to be protective against atherosclerosis
through regulation of cholesterol efflux, apoptosis, and peroxiredoxin-1 expression in mice
[60]. Additionally, similar to PAI-1, TREH is a stress response gene known to associate with
susceptibility to Type 2 diabetes [61,62].
Median regression analyses revealed novel variants associated with PAI-1 levels that would
not have been detected with linear regression. While linear regression may be appropriate for
Fig 3. Schematic of the Circadian Rhythm Pathway. Figure above was adapted from Stow et al. 2011[57]. Square indicates a significant association with
mean PAI-1 levels in Caucasian populations; circle indicates a significant association with PAI-1 levels in the current study.
doi:10.1371/journal.pone.0136379.g003
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studies with extremely large sample sizes, for studies with modest sample sizes, such as ours,
the impact of performing “standard” analyses can be significant.
Extending our analyses to include upper quartile regression allowed us to gain additional
knowledge about the differential impact of genetic variants in this clinically significant portion
of the PAI-1 distribution. Elevated PAI-1 levels are associated with increased susceptibility to
CVD and in some cases severity of disease [5,63–65]. Knowledge of genetic variation on PAI-1
levels at the higher end of the distribution may aid in the development of targeted therapies
that may not be relevant to the general population, but could have a significant impact on a
subset of the population already at increased risk of CVD.
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